[go: up one dir, main page]

CL2020000219A1 - Agente terapéutico para fibrosis. - Google Patents

Agente terapéutico para fibrosis.

Info

Publication number
CL2020000219A1
CL2020000219A1 CL2020000219A CL2020000219A CL2020000219A1 CL 2020000219 A1 CL2020000219 A1 CL 2020000219A1 CL 2020000219 A CL2020000219 A CL 2020000219A CL 2020000219 A CL2020000219 A CL 2020000219A CL 2020000219 A1 CL2020000219 A1 CL 2020000219A1
Authority
CL
Chile
Prior art keywords
fibrosis
therapeutic agent
quinas
nek6
threonine
Prior art date
Application number
CL2020000219A
Other languages
English (en)
Inventor
Kazuhisa Nakao
Junichi Ishiyama
Wataru Ichikawa
Atsushi Masui
Yunike AKASAKA
Hidekazu Toyofuku
Aya Honda
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of CL2020000219A1 publication Critical patent/CL2020000219A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE DESCRIBE UN INHIBIDOR DE LA FOSFORILACIÓN DE LA PROTEÍNA SMAD2/3 O UN AGENTE TERAPÉUTICO PARA LA FIBROSIS QUE CONTIENE COMO INGREDIENTE ACTIVO UN ÁCIDO NUCLEICO QUE SUPRIME LA EXPRESIÓN GÉNICA DE NEK6 (SERINA/TREONINA QUINASA 6 RELACIONADA CON NIMA).
CL2020000219A 2017-07-28 2020-01-27 Agente terapéutico para fibrosis. CL2020000219A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017146957 2017-07-28

Publications (1)

Publication Number Publication Date
CL2020000219A1 true CL2020000219A1 (es) 2020-07-24

Family

ID=65041024

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000219A CL2020000219A1 (es) 2017-07-28 2020-01-27 Agente terapéutico para fibrosis.

Country Status (16)

Country Link
US (1) US11326163B2 (es)
EP (1) EP3659609B1 (es)
JP (1) JP7204649B2 (es)
KR (1) KR102710473B1 (es)
CN (1) CN110996969B (es)
AU (1) AU2018307897B2 (es)
BR (1) BR112020001412A2 (es)
CA (1) CA3069406A1 (es)
CL (1) CL2020000219A1 (es)
CO (1) CO2020001106A2 (es)
EA (1) EA202090393A1 (es)
IL (1) IL272271A (es)
PH (1) PH12020500198A1 (es)
SG (1) SG11201913541QA (es)
TW (1) TW201910514A (es)
WO (1) WO2019022257A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220088057A1 (en) * 2019-01-25 2022-03-24 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
US20230357767A1 (en) 2020-08-25 2023-11-09 Bonac Corporation Novel nucleic acid molecule inhibiting expression of target gene
CN118562801B (zh) * 2024-06-13 2025-03-14 南通大学附属医院 治疗卵巢癌的siRNA分子

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040097441A1 (en) 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of NIMA-related kinase 6 expression
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
PT2933333T (pt) 2010-07-08 2018-04-24 Bonac Corp Molécula de ácido nucleico de cadeia simples para controlar a expressão génica
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
WO2012017919A1 (ja) * 2010-08-03 2012-02-09 株式会社ボナック 含窒素脂環式骨格を有する一本鎖核酸分子
CN103517913A (zh) 2011-05-10 2014-01-15 株式会社博纳克 具有同位素的磷酸化合物的制造方法
WO2013027843A1 (ja) 2011-08-25 2013-02-28 株式会社ボナック 配糖体化合物、チオエーテルの製造方法、エーテル、エーテルの製造方法、配糖体化合物の製造方法、核酸の製造方法
US9528111B2 (en) 2012-01-07 2016-12-27 Bonac Corporation Single-stranded nucleic acid molecule having amino acid backbone
CN109810977A (zh) 2012-05-26 2019-05-28 株式会社博纳克 具有递送功能的基因表达调控用单链核酸分子
JP2016522675A (ja) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
CN106102775A (zh) 2014-02-07 2016-11-09 效应物治疗公司 治疗纤维变性疾病的方法
KR102585112B1 (ko) 2014-12-29 2023-10-10 도레이 카부시키가이샤 핵산 분자를 안정하게 포함하는 조성물
HK1244031A1 (en) 2015-03-27 2018-07-27 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
CN107428793A (zh) 2015-04-02 2017-12-01 株式会社博纳克 配糖体化合物的制造方法

Also Published As

Publication number Publication date
PH12020500198A1 (en) 2020-09-28
KR102710473B1 (ko) 2024-10-02
AU2018307897A1 (en) 2020-01-30
KR20200033927A (ko) 2020-03-30
IL272271A (en) 2020-03-31
CO2020001106A2 (es) 2020-02-18
CN110996969A (zh) 2020-04-10
AU2018307897B2 (en) 2024-01-25
EP3659609A4 (en) 2021-04-21
WO2019022257A1 (ja) 2019-01-31
EA202090393A1 (ru) 2020-05-20
JPWO2019022257A1 (ja) 2020-05-28
TW201910514A (zh) 2019-03-16
CN110996969B (zh) 2023-02-28
US11326163B2 (en) 2022-05-10
BR112020001412A2 (pt) 2020-08-04
EP3659609B1 (en) 2024-05-08
US20210087556A1 (en) 2021-03-25
JP7204649B2 (ja) 2023-01-16
SG11201913541QA (en) 2020-02-27
EP3659609A1 (en) 2020-06-03
CA3069406A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MX2021004282A (es) Construcciones de ácido nucleico y métodos de uso.
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
BR112017004393A2 (pt) formulações de anticorpo
MX2016016364A (es) Terapia de combinacion con inhibidores de glutaminasa.
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
UY37379A (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
MX386292B (es) Aplicador de precision
MX2018009861A (es) Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
CL2020000219A1 (es) Agente terapéutico para fibrosis.
JOP20190262B1 (ar) مثبطات بيرازول magl
AR103215A1 (es) Composición farmacéutica que comprende plasminógeno y usos de este
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
CL2018001775A1 (es) Unidades de administración de agroquímicos de liberación controlada, su fabricación y uso
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
CO2019013035A2 (es) Heteroaril fenil aminoquinolinas y sus análogos
MX2017016774A (es) Agente terapeutico para la fibrosis.
BR112018073862A2 (pt) composição para cuidado dos cabelos
MX2016016928A (es) Composiciones parasiticidas que comprenden derivados de indol, metodos y usos de los mismos.
CL2019002636A1 (es) Agente para el control de enfermedades en plantas.
MX2017009863A (es) Agente preventivo y/o terapeutico de enfermedad inmune.
AR109407A1 (es) Compuesto de 1-acetil-3-fenilurea y su uso